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Abstract
The ongoing spread of tuberculosis (TB) in poor resource countries and the recently increasing incidence in high
resource countries lead to the need of updated knowledge for clinicians, particularly for pediatricians. The purpose
of this article is to provide an overview on the most important peculiarities of TB in children. Children are less
contagious than adults, but the risk of progression to active disease is higher in infants and children as compared
to the subsequent ages. Diagnosis of TB in children is more difficult than in adults, because few signs are
associated with primary infection, interferon-gamma release assays and tuberculin skin test are less reliable in
younger children, M. tuberculosis is more rarely detected in gastric aspirates than in smears in adults and
radiological findings are often not specific. Treatment of latent TB is always necessary in young children, whereas it
is recommended in older children, as well as in adults, only in particular conditions. Antimycobacterial drugs are
generally better tolerated in children as compared to adults, but off-label use of second-line antimycobacterial
drugs is increasing, because of spreading of multidrug resistant TB worldwide. Given that TB is a disease which
often involves more than one member in a family, a closer collaboration is needed between pediatricians and
clinicians who take care of adults.
The aim of this review is to provide updated knowledge
on childhood tuberculosis (TB), emphasizing the pecu-
liarities in transmission, natural history, clinical features,
diagnosis and treatment of TB in children. Knowledge
of clinical peculiarities of pediatric TB is now very
important because of its ongoing spreading in poor
resource countries and its recently increasing incidence
in high resource countries [1,2]. This event has been
associated to immigration of individuals from high-
endemic areas (such as Asia, Africa, South America and
Eastern Europe) to low-endemic countries (i.e. Western
Europe and United States), as well as to lack of surveil-
lance systems in low-endemic countries in the last dec-
ades. On the other hand, improved diagnostic strategies
in high resource countries favour early TB recognition
in children. The World Health Organization (WHO)
estimated that 8.7 million cases of TB occurred world-
wide in 2011 [3].Most of the TB cases in 2011 occurred
in Asia (59%) and Africa (26%).
A smaller number of cases are reported in the Eastern
Mediterranean region (7.7 %), in the European region
(4.3%) and in the region of the Americas (3%). It is
estimated that pediatric cases account for 10-15% of the
global TB cases and that the majority of them occur in
infants and children under the age of 5 years [3,4].
Despite the importance of pediatric TB, there is very lit-
tle information about the epidemiology of TB in chil-
dren worldwide, since WHO data concerns only smear-
positive children [5,6].
Differences in transmission
It has long been reported that children with TB are less
contagious than adults, because they often have a pauci-
bacillary disease, are less likely to have cavitary lesions
in lungs and have a less forceful cough as compared to
the subsequent ages [7-9] . Singh et al. reported the pre-
valence of TB infection in children who, in their house-
hold, came into contact with adults with pulmonary TB
disease and shown a significant difference in contagious-
ness between smear-positive patients and smear-negative
ones [9]. Transmission occurred globally in 95 out of
281 children (33.8%), of which 65 (68.4%) were contacts
of sputum-positive adults whereas only 30 (31.6%) were
contacts of sputum-negative ones [9]. The rate of TB
transmission from smear-positive adults seems to be
very high (from 40 to 60%), even if TB transmission
from smear-negative subjects with active TB has been
clearly documented [10-14]. A limited number of studies
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reporting rates of M. tuberculosis transmission from a
pediatric case index are available in literature (Table 1)
[15-25]. Most of these involve adolescents and describe
school outbreaks [15-19]. The rate of TB transmission to
contacts of smear positive adolescents varies from 7 to
39% [15,16,18] whereas transmission to contacts of smear
positive younger children (7-10 years old) goes from 2 to
20% [20-22]. Only Molicotti et al. described an high risk
of TB transmission from a child aged 10 years, founding
an interferon-gamma release assay (IGRA) positive in 21
(72%) of 29 contacts [23]. However, the limited number
of contacts in this report and lack of information on
microscopy on respiratory specimens from the source
case do not add consistent data to this issue. Few reports
are available if the source case is a young child and they
involve infants in hospital, accounting for a transmission
rate from infants of 0-3% [24,25]. No data were available
about transmission rates from sputum-negative children,
but two recent reports from Paranjothy et al. and Baghaie
et al. showed an extensive transmission from two smear
negative children aged 9 and 15 years, showing that
transmission of M. tuberculosis from smear-negative chil-
dren is possible [17,19]. However it is not clear if con-
tacts involved in these reports have some other risk
factors for TB, for example being household contacts of
adults with TB [18,20].
Finally, a recent systematic review by Roberts et al.
came to the conclusion that transmission to close
contacts in school outbreaks are higher if the source
case is a child 3 to 11 years of age rather than an adult
[10]. In summary, since details on children’ own risk
factors and type and duration of contact with the source
case are lacking in the majority of these reports, further
studies are necessary to elucidate contagiousness of
young children in the community.
Clinical peculiarities
Natural history
Infection with M. tuberculosis can lead to a variety of
outcomes which are generally different in children and
adults. In the pediatric age the time between infection
and the development of symptomatic disease is often
very short. Without an adequate treatment, the risk of
progression to active disease has been estimated to be
higher in infants (30-40% in those younger than 1 year
of age) and children (24% in 1-5 years of age) as com-
pared to the subsequent ages. The risk of progression
increases again in adolescence (15%), whereas in adults
is about 5-10% [6]. Following the inhalation of mycobac-
teria, innate immunity controls infection in immune-
competent patients. Tubercle bacillus initially lodges in
the lungs and immunity prevents dissemination. The
enlarged regional lymph node on chest radiograph,
which may be associated with Ghon focus, is the hall-
mark of primary TB. In this phase children are often
asymptomatic or have unspecific respiratory signs.
Table 1 Transmission rate of tuberculosis from pediatric index cases[15-25]. n.a. = not available
Index case (age/
smear)
Transmission rate to pediatric
contacts
n (%)
Transmission rate to adult
contacts
n (%)
Transmission rate to
contacts
n (%)
Reference
9 years
Smear positive
n.a. n.a. 56/27 (20%) Curtis et al, 1999 [20]
7 years
Smear positive
22/169 (13%) 19/49 (38,7%) 41/218 (18,8%) Cardona et al, 1999 [21]
4 months
Smear positive
0/44 (0%) 1/142 (0,7%) 1/186 (0,5%) Ciofi degli atti et al, 2011
[25]
7 years
Smear positive
1/16 (6,7%) 4/211 (1,9%) 5/227 (2,2%) Lee et al, 2005 [22]
10 years
n.a.
21/29 (72,4%) n.a. 21/29 (72,4%) Molicotti et al, 2008 [23]
16 years
Smear positive
67/765 (8,7%) 0/172 (0%) 67/937 (7,1%) Caley et al, 2010 [18]
9 years
Smear negative
85/200 (42,5%) n.a. 85/200 (42,5%) Paranjothy et al, 2008
[19]
4 months
Smear positive
n.a. n.a. 17/525 (3,2%) Reynolds et al, 2006 [24]
15 years
Smear positive
58/559 (10,3%) 7/67 (10,4%) 65/626 (10,3%) Phillips et al, 2004 [15]
13 years
Smear positive
195/486 (40%) 12/40 (30%) 207/526 (39,3%) Sacks et al, 1985 [16]
15 years
Smear negative
20/52 (37,7%) 0/15 (0%) 20/67 (29,8%) Baghaie et al, 2012 [17]
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Tubercle bacillus can multiply and the infection can
progress to a caseating lesion and mycobacteria can
spread, leading to haematogenous dissemination
(meningitis or miliary disease). This occurs more often
in infants and young children than in immune-compe-
tent adults [26,27]. Children are in fact prone to develop
extra-pulmonary TB; about 4% of children infected
under the age of 5 years, in fact, develop tubercular
meningitis or miliary TB [27].
Latent TB infection (LTBI)
LTBI is a very old definition, introduced in 1909 from
von Pirquet who observed positive tuberculin reactions
in children who did not have any TB clinical features
[28]. Since that time, LTBI indicates a subject with TB
infection without progression to active TB. Accordingly
to international guidelines LTBI is therefore commonly
diagnosed in asymptomatic children who have a normal
chest X-ray (or with evidence of healed infection) and a
positive tuberculin skin test (TST) or IGRA result
[29,30]. Most guidelines, in the past, recommended to
consider positive any TST result > 10 mm diameter (or
any result > 5 mm if recently exposed to TB or immu-
nocompromised), independently from vaccination with
BCG. Recently, at the light of new evidences, UK gui-
dance on TB recommend to consider a TST positive if
induration is > 6 mm diameter for non vaccinated and
> 15 mm for Bacille Calmette-Guerin (BCG) vaccinated
subjects [30]. Moreover, recently, the concept of LTBI
has been partially revised. LTBI was considered to be
associated with a low number of dormant mycobacteria
and the subject was considered to be infected, but not
ill nor infectious. There are now some evidences that
LTBI is a quite complex clinical condition, with a
dynamic equilibrium between latency (characterized by
absence of mycobacterial replication) and active disease
[31]. This may be particularly true in childhood when,
in recently exposed children, the boundary line between
primary TB and LTBI may be hardly defined.
Pulmonary tuberculosis
Pulmonary TB includes intrathoracic lymphadenopathy
and parenchymal disease. In children, the infection in
the lung is often characterized by a Ghon focus with
regional lymphadenitis, called “primary complex”. Pri-
mary TB can rapidly progress, especially in younger
children, to lung tissue destruction and a caseating cav-
ity formation (progressive primary TB). Instead in
adults, active pulmonary TB more frequently represents
a secondary reactivation of a latent TB infection [32].
Primary focus is subpleural in 70% of cases and in 25%
of cases the foci are multiple. The lesions usually affect
the lobes with greatest ventilation, i.e. the right upper
and middle and the left upper lobe [33]. Children can
develop a lobar pneumonia and the colliquative necrosis
of the lung parenchyma may lead to the formation of a
cavity. Calcifications in children are not commonly seen
on chest X-rays. The presence of calcifications indicates
that the lesion has been present for at least 6-12 months
[34,35]. Pleural involvement may be due to a direct
spread of caseous materials from a subpleural lesion or
lymph nodes [32], but it is also thought to be the result
of a hypersensitivity reaction to mycobacterial antigens.
Detection of M. tuberculosis in pleural fluid is therefore
possible in only about 56% of children with TB, but
biopsy of pleural tissue has a higher culture yield [35].
Pleural TB is uncommon in children under the age of 6
years, and it is rare in those younger than 2 years of
age; instead, it has commonly been observed in adoles-
cents [32,36]. The most common clinical features of
pulmonary TB in young children are non productive
cough, low fever and, in rare cases, weight loss. Wheez-
ing, which is usually secondary to extrinsic compression
by ilar lymphonodes or even to lumen reduction by
endobronchial granulomas, may occur particularly in
younger children because of the small airways caliber
[37].An unusual clinical finding, especially in low
resource countries, is croup, due to a laryngeal TB with
granulation tissue of the glottis. The infection of the
glottis can be either due to the direct spread from the
bronchus to the larynxor to hematogeneous spread [38].
Gie et al. reported that among 354 children initially sus-
pected of suffering from TB, 71 (20%) were found to
have other pulmonary diseases such as pneumonia
(29%), bronchopneumonia with wheezing (18%) ad
asthma with lobar or segmental collapse (12%) [37].
Radiological evidences of pulmonary TB in children are
less specific than in adults [39]. Adult type disease is dis-
tinguished by cavitation that occurs predominantly in the
lung apices, in the posterior segment of the upper lobes
and in the superior segments of the lower lobes. In
younger children the most common radiological findings
are non specific lesions and the most typical feature is
hilar or paratracheal lymphadenopaty [40]. Adult type
disease may occur in adolescents, who usually develop it
within 2 years after primary infection [39]. A study car-
ried out in Nigeria investigated the radiological features
of TB in 423 patients including 47 children. The most
common radiological features in adults were cavitary for-
mations, streaky opacities and nodular opacities, whereas
the most common findings in children were hilar lym-
phadenopathy, bronchopneumonia and pleural fluid col-
lections [40]. The enlargement of lymph nodes is not
often visible in chest X-ray, partially because of the pre-
sence of the thymus, and the chest X-ray may appear
normal. A recent study carried out in asymptomatic chil-
dren with TB infection has reported that the frequency of
chest X-ray abnormalities was only 1,8% [41]. Therefore,
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differential diagnosis between active and latent TB are
not always easy and a computed tomography (CT) scan
with contrast may often be helpful. Enlarged lymph
nodes may be detected by CT scan in 60% of children
with normal finding on chest X-ray [42].
Tubercular lymphadenitis
The most common manifestation of extrapulmonary TB
in the pediatric age is tubercular lymphadenitis. This is
part of the primary complex and in children it usually
develops within 6 months from infection [27]. More
common than in adults, the enlargement of regional
lymph nodes as result of TB usually occurs in response
to a pulmonary focus within their drainage area and it
generally involves cervical, submandibular, supraclavicu-
lar, preauricular or submental areas [27,43].
Central Nervous System (CNS) tuberculosis
The most severe manifestations of extra-pulmonary TB
in children, as well as in adults, are those occurring in
the CNS. Tubercular meningitis (TBM) is more com-
mon in early childhood, whereas tuberculoma is usually
(but not exclusively) found in older children and adults.
Uysal et al. recently reported that, excluding the lymph
nodes, the most commonly involved site in childhood
extra-pulmonary TB is the CNS [44]. Even with anti-
tubercular therapy, TBM short-term mortality is high,
ranging from 20 to 69% with permanent neurological
sequelae occurring in 50% of cases [45,46].
TBM occurs in children more frequently within 2
years of primary infection, predominantly in infants
under the age of 5 years [47,48]. The onset is often gra-
dual with non-specific symptoms and diagnosis is conse-
quently difficult. In a recent study conducted in adult
and pediatric patients with TBM, the most common
signs and symptoms were headache (69%), fever (69%),
nausea/vomiting (61%), anorexia (54%), altered mental
state (58%),weight loss (37%), cough (33%) and drowsi-
ness (28%) [49]. Tuberculoma typically occurs in cere-
bellum in children and in the frontal lobe in adults [27].
The presenting signs are essentially those of a space-
occupying lesion: headache, nausea/vomiting and focal
neurological signs, and they may differ in children and
adults because of the typical different localization of
tuberculoma [50-52].
Bone tuberculosis
Bone and join lesions are more frequent in childhood
than in adult age and occur up to 5% of all pediatric TB
cases [27]. Skeletal TB usually is a disease of the older
child, with the exception of spinal involvement, which
can occur even in younger children. The most common
manifestations of skeletal TB are osteomyelitis, spondyli-
tis and arthritis [32]. Osteomyelitis can occur in any
bone and can be multiple but tuberculous dactylitis and
thoracic and lumbar spinal TB (Pott’s disease) are the
most common manifestations in young children. Pott’s
disease accounts for up to 40% of bone TB in children,
whereas it is rare in adult population [27]. Moreover, ver-
tebral destruction is more severe in children than in
adults because bones are mostly cartilaginous [53]. How-
ever, M. tuberculosis does not produce proteolytic
enzymes that can destroy cartilage. Hence there is poten-
tial for preservation of good function when early diagno-
sis is made[27]. Usually immune-competent children
have solitary lesions, whereas multiple lesions are com-
mon in immune-compromised pediatric patients [32].
All the clinical manifestations listed above are the
more frequent ones observed in pediatric TB. Less com-
mon manifestations are summarized in Table 2 [53-72]
Table 2 Clinical manifestations of tuberculosis in children [53-72]
Area involved Clinical presentation
More common
Lungs and airways Pneumonia, cavitary lesions, wheezing, laryngeal involvement
Lymph nodes Enlargement of mediastinal, cervical, submandibular, supraclavicular, preauricular, submental and abdominal lymph nodes
Central nervous system Meningitis, tuberculoma
Bones and skeletal
muscles
Pott’s disease, arthritis, cystic of bone, abscess of skeletal muscles
Less common
Abdomen Pneumatosis intestinalis, peritonitis, liver and splenic abscess, enterolithiasis, intestinal perforation
Genitourinary tract Scrotum inflammation, hydrocele, calyceal destruction, ureteral strictures, small-capacity bladder, hydronephrosis, kidney
calcification
Heart and vessels Intracardiac tuberculoma, pseudoaneurysms
Oral cavity Enlargement of the tonsils, rethropharyngeal abscess, granulomatous cheilitis
Eyes Uveitis, episcleritis, optic neuritis, orbital tuberculoma
Skin Scrofuloderma lesions, lupus vulgaris, tuberculosis verrucosa cutis
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Diagnostic peculiarities
Diagnosis of TB in children is commonly obtained using
the Tuberculin Skin Test (TST) and Interferon Gamma
Release Assays (IGRAs), associated to radiological tech-
niques. However, the gold standard for diagnosis of
active TB is the detection of M. tuberculosis clinical spe-
cimens. IGRAs are immunological tests which are based
on the important role that interferon-gamma plays in
immunological response to M. tuberculosis. They are
extensively dealt with in a dedicated chapter in this
supplement.
Tuberculin Skin Test (TST)
TST available are the Mantoux test and the multi-
puncture test, but only the Mantoux test is a standar-
dized method. Hence, the Mantoux test is the preferred
test for detecting infection by M. tuberculosis and it is
currently reported as a synonym of TST. A positive
TST reaction is a hallmark of TB infection, but it does
not distinguish between latent infection and disease.
Tuberculin reactivity usually becomes apparent in 6
weeks, but occasionally can take up to 3 months after
infection [73].
False-negative results in adults may occur in patients
with immunosuppressive illness, malnutrition, viral
infections (such as Human Immunodeficiency Virus
infection, influenza, measles and chickenpox) and active
disseminated TB. False-negative results in children can
be due to the same conditions or only to the young age.
Sensitivity is lower in children than in adults. Two
recent meta-analysis reported a 80-82%sensitivity of
TST in active disease in children [74,75]. By contrast,
other authors found a 94%sensitivity in adults [76].
Therefore, after a recent exposure to a source case of
TB, a negative TST result does not exclude the diagno-
sis of TB, particularly in young children. In adults and
children who are older than 5 years, a negative result
obtained <8 weeks after exposure is considered unreli-
able for excluding infection and a follow-up test at the
end of the window period is therefore necessary. In chil-
dren under the age of 5 years, the low sensibility of TST
and the higher risk of progression of TB infection justify
a more timely therapeutic attitude. So far, in this age
group, treatment for suspected M. tuberculosis infection
(window prophylaxis) is recommended also if the initial
skin test induration diameter is <5 mm. Only after a
second TST administered 8 weeks post-exposure (and
absence of clinical and radiological abnormalities) the
decision to treat or not to treat is reconsidered [77].
False-positive TST can result from vaccination with
(BCG) or after contact with non tuberculous mycobac-
teria (NTM), since the purified protein derivative (PPD)
contains a mixture of over 200 antigens including some
antigens common to BCG and NTM [78,79].
Detection of M. tuberculosis in sputum or gastric aspirate
The gold standard for diagnosis of active TB is the
detection of M. tuberculosis in clinical specimens. Spu-
tum microscopy is the most useful test in adults for
diagnosis worldwide even though it has a sensitivity of
60% or less, mainly because a positive smear requires at
least 5000-10000 acid-fast bacilli (AFB) per μL sputum
sample. An added value of smear microscopy, thanks to
the semiquantitative score, is its possible use for therapy
monitoring. Culture for M. tuberculosis takes 8 weeks to
be considered negative but following the implementa-
tion of liquid media, on overage 80% of positive results
are reported in less than 20 days. It requires only
10-100 AFB per μL, and can detect pulmonary TB in
around 80% of cases [80]. Nucleic acids amplification
can provide results within 24-48 hours and performs
well on smear-positive specimens with a sensitivity close
to 100%; the sensitivity is in contrast suboptimal on
smear negative sample [81,82].
Detection of M. tuberculosis in sputum is even more
difficult in children for at least two reasons. Firstly, as
young children are frequently unable to expectorate, a
number of procedures have been suggested to obtain
samples from the lower respiratory tract. The collection
of three consecutive early morning gastric aspirate sam-
ples, is widely used with the aim of recovering swal-
lowed sputum for microbiological confirmation in
children. A number of less invasive alternative methods
have been recently proposed, including induced sputum,
nasopharyngeal aspiration and the string test. Secondly,
because of the paucibacillary nature of TB disease in
children, smears from sputum or from gastric aspirates
are positive in less than 15% of children diagnosed with
TB and a positive culture is achieved only in less than
40% of cases and even lower is the sensitivity of the
nucleic acids amplification [83]. Therefore, investigations
in sputum or in gastric aspirate can have a poor perfor-
mance in identifying active TB in children [84,85].
Microbiological diagnosis of different forms of extrapul-
monary TB does not substantially differ in children and
adults. Cerebrospinal and lymphonodal are the most fre-
quent extrapulmonary TB localizations in children. The
diagnosis of cerebrospinal TB is challenging mainly in
consequence of the extremely low number of bacilli due
to the limited volume of cerebrospinal sample usually
available, its subdivision between multiple tests is often
self defeating and the highest sensitivity is achieved
using the whole sample for the culture in liquid medium
only. The nucleic acid amplification tests too may pre-
sent reasonable sensitivity, at least with systems accept-
ing large volume of sample (up to 2 mL) [86]. The
microbiological diagnosis of lymphonodal TB is not pro-
blematic once a proper sample (fine needle aspirate or
biopsy) is available. In this case, in particular in presence
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of cervico-facial localization, the differentiation of tuber-
cular from non-tubercular etiology is crucial and may be
confidently achieved by resorting to methods based on
reverse hybridization, which are commercially available.
Because of the increase of drug-resistant TB the sus-
ceptibility testing is essential for every newly diagnosed
case. The phenotypic test, which is the gold standard,
performs well in particular for the major drugs rifampi-
cin and isoniazid; it takes on overage two weeks once
the strain has grown in culture. In presence of Multi-
Drug-Resistant TB (MDR-TB) the antimicrobial suscept-
ibility testing to second line drug is needed; because of
standardization problems it should be performed by
reference laboratories only. In the last years a number
of mutations have been detected which are responsible
for resistance to different drugs. The recognition of spe-
cific mutations in certain genetic regions is predictive of
resistance. Commercially available molecular methods
can detect mutations responsible of resistance on strains
grown in culture or directly on smear positive clinical
specimens. They are able to detect rifampicin resistance
in more than 95% of rifampicin-resistant strains [87].
Rifampicin resistance is often considered a surrogate
marker of MDR-TB as about 90% of resistant strains are
resistant to isoniazid too. Methods suitable to detect
mutations responsible of resistance to other drugs are
also offered, although very specific, they are character-
ized by sensitivity clearly lower than that of rifampicin
[Table 3].
In summary, there is a need for improved accuracy of
the diagnosis of TB in children. In adults smear and
sputum culture provide reliable standards because of the
diagnosis is usually confirmed microbiologically [66]. In
contrast, in children there is a lack of a standardized TB
case definition and epidemiological, clinical and radiolo-
gical findings are always needed to make diagnosis of
TB. Some experts in pediatric TB have recently pro-
posed clinical case definition categories (confirmed, pos-
sible, probable, unlikely, or not TB) for intrathoracic
disease in children. Children with confirmed TB are
those who have at least one sign or symptom suggestive
of TB and microbiologically confirmed TB. Children
with probable TB are those who have at least one sign
or symptom suggestive of TB and a suggestive chest
radiography and a positive clinical response to anti-
tuberculosis treatment or a documented exposure to M.
tuberculosis or immunological evidence of M. tuberculo-
sis infection. Children with possible TB are those who
have at least one sign or symptom suggestive of TB and
a suggestive chest radiography or a positive clinical
response to anti-tuberculosis treatment or a documen-
ted exposure to M. tuberculosis or immunological evi-
dence of M. tuberculosis infection. Children with
unlikely TB are those with only signs or symptoms sug-
gestive of TB. Children in whom TB may be excluded
are those without signs or symptoms suggestive of TB
and with an alternative diagnosis [88].
Treatment of TB
The recommended treatment regimens for latent and
active TB are generally the same for children as for
adults. Treatment of latent TB infection is always neces-
sary in children, instead it is not recommended in adults
aged more than 36 years because of the increasing risk of
hepatotoxicity of drugs with age and because of latent TB
in adults is rarely due to a recent infection. Treatment is
necessary if adult patients are infected with HIV (because
of the major risk of active TB development) or if they are
healthcare workers (because of the risk of transmission of
M. tuberculosis among patients) [89]. Treatment for
latent TB involves the use of one or two anti-tubercular
agents to prevent the future development of TB disease.
Three regimens, containing isoniazid or/and rifampicin,
are now recommended for treatment of latent TB in chil-
dren by the international guidelines [89-93]. Randomized
trials have shown that treatment with isoniazid is highly
effective, with 90% protection provided by completion of
9 months and 60-80% protection provided by completion
of 6 months in adults [90,93]. In children, treatment with
isoniazid for 9 months provides protection to approxi-
mately 100% . Adverse events associated with isoniazid
are generally mild, such as nausea or headache, but can
include rashes, hepatitis and peripheral neuropathy. The
most serious complication is isoniazid-induced hepatitis,
which can progress to fulminant hepatic failure and
death [94]. Also treatment with rifampicin for 4 months
is recommended in adult population and for 6 months in
childhood [89-91]. Although not recommended by all the
international guidelines, the 3-month regimen of both
rifampicin and isoniazid is often used as alternative regi-
men in adults and children [90,92]. In a meta-analysis of
four small randomized trials, this regime appeared to
provide 60% protection in adults but in children data
about its effectiveness are not available [94].
Table 3 Gene investigated for mutations responsible of
resistance to different drugs and sensitivity percentage
of resistant strains presenting mutation in the particular
gene [85].
Drug Gene arbouring
mutations
Sensitivity
Rifampicin rpoB > 98%
Isoniazid katG, inhA 80-90%
Quinolones girA 70-90%
Amikacin, Capreomycin,
Kanamycin
Rrs 50-90%
Ethambutol embB 70-80%
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Isoniazid, rifampicin, pyrazinamide and ethambutol
are the first-line drugs in the treatment of active TB dis-
ease in adults and in children. The most common
regime used is a two-month intensive phase of daily iso-
niazid, rifampicin and pyrazinamide followed by a four-
month continuation phase of daily isoniazid and rifam-
picin. In the first two months, the addition of a fourth
drug such as ethambutol or a second-line anti-tubercu-
lar drug is necessary in complicated pulmonary TB or in
meningeal involvement and, in addition, can protect
against the emergence of drug resistant organisms [89].
Ethambutol was not recommended for use in children
aged less than 5 years because optic neuritis (the most
common form of toxicity which can lead to irreversible
blindness) is difficult to monitorize in younger children
[95]. Recent studies have shown that ocular toxicity
occurs in children taking high or prolonged doses of
ethambutol. Thus, if the recommended dosages are
adhered to it is now considered safe in children. In fact,
a review of Donald et al. reported that among 3811 chil-
dren who had received ethambutol, only two (0,05%)
have developed ocular toxicity [83]. Therefore, screening
children for ethambutol ocular toxicity seems unneces-
sary [97].
Until recently, recommended dosages in mg/kg for
antitubercular agents in children were deducted from
dosages used in adults. Dosages of first-line anti-tuber-
cular drugs in children have been increased in 2009 by
WHO, because several pharmacokinetic studies have
shown that infants and young children have lower peak
serum levels than adolescents and adults, because of a
different rate of metabolism, clearance and distribution
of drugs [98,99]. This concept has been recently con-
firmed by Verhagen et al. in a pharmacokinetic study
coming from Venezuela and involving children younger
than 16 years of age [100]. In addition, children tolerate
anti-tubercular agents better than adults, partially
because of a lower prevalence of underlying liver disease
and alcohol usage [101]. A recent study has reported
that these doses are safe also in children under the age
of two years, in whom few studies on first-line drug
pharmacokinetic are available [102]. The doses of first-
and second-line anti-tubercular drugs recommended by
the most recent international guidelines are listed in
Table 4. The incidence of anti-tubercular drug-induced
hepatotoxicity has been variably estimated between 2%
and 28%, but studies concerning children are limited
and include reports in which children and adults are
evaluated together [103-105]. A recent review has
reported that although anti-tubercular drug-induced
hepatotoxicity can occur in children at any age or with
any dosage of drugs, the incidence of it is considerably
lower than in adults. In fact, among 12,708 children
receiving chemoprophylaxis only one case of jaundice
was recorded and abnormal liver functions were docu-
mented in 8% of the children studied [101]. In adults,
older age seems to be a risk factor for hepatotoxicity,
whereas younger children have been reported to be at
lower risk [106,107]. However, children with dissemi-
nated forms of disease seem to be at greatest risk of
anti-tubercular drug-induced hepatotoxicity [101].
However, the emergency of MDR-TB has led to an
increase of use of second-line anti-TB drugs and also of
drugs with unclear effectiveness against M. tuberculosis
both in adults and children [108]. Despite the fact that
most of these agents were discovered many years ago,
information is lacking regarding their pharmacokinetic
and pharmacodynamic proprieties, adverse effects and
drug interactions in children and therefore they are not
formally approved for use in childhood by Food and
Drug Administration. Given the increased incident of
MDR-TB, to include children in trials of novel or existing
agents is now a priority [109]. There are several barriers
to include children in TB drugs development: infrequent
transmission of TB from children, difficulty of confirming
active tuberculosis among children, existent of effective
therapy for drug susceptible TB, concerns about pedia-
tric-specific side effects, uncertainties about the appropri-
ate time to involve children in drug development,
regulatory requirements engendered by the inclusion of
children and concerns about further subdividing the lim-
ited resources available for drugs development [110].
Confirmation of MDR-TB may not be possible in chil-
dren because of the paucibacillary nature of TB and
information about the response to treatment of the index
case is often needed. In addition, the second-line drugs
are not available in pediatric formulations or appropriate
table size and therefore dosing may be inaccurate and
sub-therapeutic or toxic level are possible. Hence,
although their use is often necessary because of the emer-
gence of MDR-TB, carefulness is necessary in off-label
use of these medications in children and more studies
and multicenter trials should be conducted in children,
to test the effectiveness and the safety of anti-tubercular
second-line drugs [111]. Seddon et al. have recently
demonstrated that hearing deficit is common in children
treated with aminoglycosides and polypeptides and this
can have profound implications for developmental of lan-
guage. Children should be screened prior to begin treat-
ment and then they should be monitor for hearing at
least every month [112]. Ethionamide treatment instead
may cause hypothytoidism as in developing children as in
adults and the risk is higher for children on regimens
including para-aminosalycilic acid and for HIV-infected
children [113].
It is also important to note that ensuring compliance
to treatment is a major challenge. This is even more
true in children, whose major problems are the low
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palatability of medications and the daily pill burden. In
fact, the daily pill burden can be vast in children
because they may require multiple medications due to
the few fixed dose drug combinations approved for
pediatric age. Hence, good communication between the
hospital team, general practitioner or pediatrician,
patient and care givers is necessary to make the patient
and the family understand that taking the medication is
the better option [114].
The differences in treatment of TB between children
and adults are summarized in Table 5, where the most
important differences in transmission, natural history,
clinical features and diagnosis of TB between pediatric
and adult age are also listed.
Conclusions
The recently increasing incident of TB in high resource
countries has led to a rise of interest in this condition,
particularly by pediatricians, because this finding has
been especially observed in children. Hence pediatricians
have to deal with an emerging disease, first considered
almost disappeared and then little is known about it. In
this review we provide information on childhood TB,
emphasizing the most important differences in transmis-
sion, natural history, clinical features, diagnosis and
treatment of TB between children and adults. Infection
with M. tuberculosis can lead to a variety of outcomes,
which are generally different between children and
adults, and this confirms the well known concept that
“the child is not a small man”.
The knowledge of peculiar clinical features of child-
hood TB allows a prompt diagnosis and a prompt treat-
ment which are very important for at least three
reasons. Firstly, children carry the greatest burden of
developing disease and extrapulmonary involvement. In
particular, tuberculous meningitis and miliary TB occur
Table 4 Doses of first- and second-line anti-tubercular drugs recommended in adults and in children [30,93,98,111].
qd= ones a day; bid= twice a day; tid= three times a day.
Anti-tubercular drugs Dosages in adults
(mg/kg)
Dosages in children
(mg/kg)
First-line anti-tubercular drugs
Isoniazid 4–6qd 10–15 qd
Rifampicin 8–12 qd 10–20 qd
Pyrazinamide 20–30 qd 30–40 qd
Ethambutol 15–20 qd 15–25 qd
Second-line anti-tubercular drugs Dosages in adults
(mg/kg)
Dosages in children
(mg/kg)
Capreomycin 15-30 qd 15-30 qd
Kanamycin 15-30 qd 15-30 qd
Amikacin 15-20 qd 15-30 qd
Streptomycin 12-18 qd 20-40 qd
Levofloxacin 7,5-10 qd 7,5-10
qd in children aged ˃ 5
bid in children aged ˂ 5
Moxifloxacin 7,5-10qd 7,5-10 qd
Ofloxacin 15-20qd 15-20 qd
Ethionamide 15-20 qd 15-20 qd
Protionamide 15-20 qd 15-20 qd
Cycloserine 15-20 qd 10-20 qd
Para-amino-salicylic acid (PAS) 150 qd 200-300 qd
Anti-TB drugs with unclear efficacy Dosages in adults
(mg)
Dosages in children
(mg/kg)
Linezolid 600 qd 10 qd
Clarithromycin 500 bid 7,5 bid
Clofazimine 200qd 1 mg/kg qd
Meropenem 2000 tid 20-40 tid
Amoxicillin/clavulanate 2000/250 bid (maximum dosage)* 40 bid (based on amoxicillin component)*
* Recommended dosage of amoxicillin/clavulanate in adults and children is not clear because of the amoxicillin to clavulanate ratio in commercially available
tables and oral suspensions goes from 2:1 to 7:1.
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more often in children than in adults. Secondly, they
represent the pool from which a large portion of future
and contagious cases of adult TB will arise. Finally,
because disease in young children reflects recent infec-
tion, rather than secondary reactivation as in adults,
childhood TB may be considered as a marker of current
transmission in the community and therefore the diag-
nosis of TB in children is also a public health problem
and it should always lead to the research of a source
case, which, considering that children are rarely conta-
gious, is often an adult.
Despite its importance, prompt diagnosis of TB in
children is more difficult than in adults because it is
complicated by the low number of signs and symptoms
in primary infection, the unreliability of IGRAs in chil-
dren under the age of 5 years, the lower sensibility of
TST in infants than in adolescents and adults, by the
more difficult detection of M. tuberculosis in gastric
aspirates than in sputum-smear in adults and by the
non specific radiological findings of primary complex,
which is more frequent in children than it is in adults.
Hence, further research is needed to develop more sen-
sitive tests for diagnosis of TB in children.
Promptness to make diagnosis allows early treatment
with anti-tubercular agents, which greatly improves the
prognosis of patients. Despite the risk of causing major
side effects, such as drug-related hepatotoxicity, is less
frequent in children than in adults, particular attention
is necessary during the follow-up of the young patients
to identify any adverse events of anti-tubercular drugs,
particularly when they are treated with second-line anti-
tubercular drugs for MDR-TB.
Moreover, given that TB is a disease which often
involves more than one member of a family from differ-
ent age groups, a closer collaboration is necessary
between pediatricians and clinicians who take care of
adults.
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Table 5 Summary of differences in tuberculosis between adults and children.
Category Adults Children
Transmission are frequently contagious because they often
have:
- cavitary lesions
- multibacillary disease
- pulmonary tuberculosis
- less circumscribed social networks
- more forceful cough
- productive cough
are infrequently contagious because they often have:
- non-cavitary lesions
- paucibacillary disease
- extrapulmonary tuberculosis
- more circumscribed social networks
- less forceful cough
- non-productive cough
Natural
history
- risk of progression is 5-10%
- time between primary infection and
disease is often long (some years)
- risk of progression is:
45% in infants < 1 year of age;
24% in children 1-5 years of age;
15% in adolescents
- time between primary infection and disease is often short (1-6 months)
Clinical
presentation
- primary infection is often asymptomatic but
symptoms and signs are specific
- principally develop pulmonary TB
- primary infection is asymptomatic but it may rapidly progress to symptomatic TB
disease with not specific symptoms and signs
- often develop extrapulmonaryand military TB
Diagnosis - for screening purposes TST or IGRAs are
recommended
- detection of M. tuberculosis in sputum
smear is achieved in 80% of cases
- chest radiography shows cavitary
formations
- in children < 5 years of age only TST is recommended because IGRAs may be
unreliable
- in children ˃ 5 years of age and adolescents TST or IGRAs are recommended
- detection in gastric aspirates of M. tuberculosis is achieved in less than 40% of cases
- chest radiography shows unspecific lesions (e.g. hilar or mediastinal
lymphadenopathy, bronchopneumonia and pleural fluid collections) or may be
normal
Treatment - treatment for latent TB in close contacts
should be unnecessary
- toxicity induced by anti-tubercular drugs is
most common
- use of second-line anti-tubercular agents is
formally approved
- fixed dose drug combinations are available
- treatment for latent TB is always necessary and in close contacts< 5 years it should
be started also if TST is negative
- toxicity induced by anti-tubercular drugs is less common (also ethambutol is
considered safe in young children)
- use of second-line anti-tubercular agents is not formally approved
- few fixed dose drug combinations are available
TB= tuberculosis; TST= Tuberculin Skin Test; IGRAs = Interferon-gamma Release Assays.
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